A new CRISPR-based tool that is directly used on patients' cancer cells can identify genes and regulatory elements driving ...
How innovative technologies like AI and gene editing are advancing rare disease drug discovery and development.
A new CRISPR-based tool that is directly used on patients' cancer cells can identify genes and regulatory elements driving acute myeloid leukemia (AML), an aggressive blood cancer affecting the bone ...
We are very pleased to have aligned with the FDA on the path forward for our MAGNITUDE clinical trial, with measures designed ...
ERS Genomics Limited ('ERS'), the CRISPR licensing company, today announced the launch of its Early Access Express License, a ...
Rare Disease Day is held on the last day of February to raise awareness for rare diseases and address drug development ...
Durham, North Carolina and Oxford, United Kingdom, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Pairwise, a global innovator in agriculture, today ...
13d
Gene Editing Has Struggled To Go Commercial. This Nobel Laureate Has A $1 Billion Plan To Fix That.
Crispr’s ability to cut genetic code like scissors has just started to turn into medicines. Now, gene editing pioneer ...
Exploring the promising potential and challenges of organoids in esophagus and esophageal squamous cell carcinoma research Esophageal squamous cell ...
Cathie Wood's ARK Invest bought Recursion Pharmaceuticals and CRISPR Therapeutics while selling PagerDuty, Teradyne, and Salesforce on8, 2026.
In recent years, mRNA in lipid nanoparticles (mRNA–LNPs) has emerged as a promising strategy for treating numerous conditions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results